Sept 11 (Reuters) - Czech generic drugmaker Zentiva

said on Thursday that private equity group Advent

International had agreed to sell the company to rival GTCR for

an undisclosed value.

The deal values the Prague-based company at slightly

more than 4 billion euros ($4.69 billion) including debt,

according to a source with knowledge of the deal.

The Financial Times had first reported the deal on

Wednesday, saying it was worth 4.1 billion euros.

Zentiva was acquired by Advent from French pharmaceutical

giant Sanofi in 2018 for an enterprise value of 1.9

billion euros.

There have been reports of Advent mulling a sale of the

generics drugmaker since 2021, with companies such as Polish

drugmaker Polpharma and India's

Aurobindo Pharma

reported to be joining the race.

Zentiva supplies a wide range of generic and

over-the-counter drugs such as paracetamol and co-codamol to

more than 100 million people across Europe.

($1 = 0.8530 euros)